Johnson & Johnson completed the acquistion of 41.1% stake in Ci:z Holdings Co.,Ltd. for approximately ¥120 billion.
January 09, 2019
Share
Johnson & Johnson (NYSE:JNJ) made a tender offer to acquire additional 52.1% in Ci:z Holdings Co.,Ltd. (TSE:4924) for approximately ¥150 billion on October 23, 2018. A total of 25.4 million shares will be acquired at ¥5900 per share in cash. Johnson & Johnson directly and indirectly owns 9.7 million shares of Ci:z Holdings Co.,Ltd. and the offer is made to acquire remaining shares, except 13.6 million owned by CIC Corporation, which will not be part of tender offer. In related deal, Johnson & Johnson signed an agreement to acquire 9.7 million shares in Ci:z Holdings Co.,Ltd. from CIC Corporation. Post completion of the transactions, Ci:z Holdings Co.,Ltd. will be delisted from exchange and will operate as a subsidiary of Johnson & Johnson. The tender offer will commence from October 29, 2018 to January 10, 2019. The offer is subject to minimum tender of 9.1 million shares. The Board of Directors of Ci:z Holdings Co.,Ltd. unanimously resolved the deal on October 23, 2018 and recommend the deal to shareholders. Goldman Sachs & Co. LLC and PricewaterhouseCoopers Aarata LLC acted as financial advisor and Robert I. Townsend III, Damien R. Zoubek and J. Leonard Teti LL of Cravath, Swaine & Moore LLP and Mori Hamada & Matsumoto LPC acted as legal advisor for Johnson & Johnson. Nomura Holdings, Inc. (TSE:8604) acted as financial advisor and Nagashima Ohno & Tsunematsu acted as legal advisor for Ci:z Holdings Co.,Ltd.
Johnson & Johnson (NYSE:JNJ) completed the acquistion of 41.1% stake in Ci:z Holdings Co.,Ltd. (TSE:4924) for approximately ¥120 billion on January 10, 2019. Johnson & Johnson acquired 20 million shares at ¥5900 per share.
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows:
- pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.;
- medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals;
- consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc.
At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25).
Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
JOHNSON & JOHNSON 
